Device Trial Radar · NCT03154996
Chronic Convection Enhanced Delivery of Topotecan
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Jan 18, 2018
Primary completion
Aug 20, 2021
Study completion Aug 20, 2021
Sponsor
- Lead sponsor
- Columbia UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumor response with prolonged continuous intracerebral convection-enhanced delivery (CED).
Conditions
- Gliomas
Interventions
TopotecanDrug
Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump. Dose: 146 micrometers (uM)
GadoliniumDrug
Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
Synchromed II infusion pumpsDevice
Implanted subcutaneously to facilitate chronic infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose at which all patients have had no greater than grade 2 adverse reactionsTime frame: Up to 29 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.